Protagonist Therapeutics, Inc. (PTGX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 9.05B USD. 52-week range 65.75 to 160.81 USD. Trailing P/E 135.8. Data as of 2026-10-09.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is ...